Valuation : PREDILIFE

Market Cap 4.42M 5.12M 4.14M 3.78M 7.12M 488M 7.15M 49.19M 19.17M 247M 19.21M 18.79M 820M P/E 2024
-3.18x
P/E 2025 -3.01x
Enterprise Value 9.2M 10.65M 8.62M 7.87M 14.81M 1.02B 14.88M 102M 39.9M 514M 39.98M 39.11M 1.71B EV / Sales 2024
34.5x
EV / Sales 2025 19.3x
Free-Float
48.75%
Yield 2024 *
-
Yield 2025 -
1 week+0.90%
Current month-6.67%
1 month-6.67%
3 months-61.25%
6 months-64.22%
Current year-62.79%
1 week 1.11
Extreme 1.11
1.12
1 month 1.11
Extreme 1.11
1.5
Current year 0.9
Extreme 0.9
4
1 year 0.9
Extreme 0.9
4
3 years 0.9
Extreme 0.9
24
5 years 0.9
Extreme 0.9
24
10 years 0.9
Extreme 0.9
24
Manager TitleAgeSince
Chief Executive Officer 56 2003-12-31
Chief Tech/Sci/R&D Officer - 2006-12-31
General Counsel - 2015-12-31
Director TitleAgeSince
Chairman 56 2003-12-31
Director/Board Member 46 2017-12-31
Director/Board Member 58 2017-12-31
Date Insider Type Main position Quantity % Market Cap.
7/27/23 Buy

Chief Executive Officer

1,200 0.0328%
3/23/22 Sell

Chief Executive Officer

3,000 0.0820%
3/9/22 Buy

Chief Executive Officer

2,000 0.0546%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+0.90%-65.54%-80.00% 5.13M
-4.73%-3.08%+91.12%+277.10% 4.02B
-3.03%-3.38%+259.19%+30.88% 3.63B
-4.22%+2.43%+42.85%+64.79% 3.48B
-4.91%+2.43%+264.49%+442.37% 2.58B
-3.09%-6.35%-26.54%-26.21% 2.25B
+6.10%+7.10%+39.80% - 1.59B
+11.76%+16.89%+37.38%+60.22% 1.18B
-8.24%-11.11%+217.36%-26.30% 1.14B
-2.87%+25.09%+27.90%+184.74% 675M
Average -1.32%-0.03%+88.80%+103.07% 2.06B
Weighted average by Cap. -2.54%-0.51%+119.29%+142.22%

Financials

2024 2025
Net sales 493K 571K 462K 422K 794K 54.47M 798K 5.49M 2.14M 27.57M 2.14M 2.1M 91.46M 836K 968K 783K 715K 1.35M 92.31M 1.35M 9.3M 3.63M 46.72M 3.63M 3.55M 155M
Net income -4.26M -4.94M -4M -3.65M -6.87M -471M -6.9M -47.47M -18.5M -238M -18.54M -18.13M -791M -3.93M -4.56M -3.69M -3.37M -6.33M -435M -6.36M -43.79M -17.07M -220M -17.1M -16.73M -730M
Net Debt 3.54M 4.1M 3.32M 3.03M 5.7M 391M 5.72M 39.38M 15.35M 198M 15.38M 15.05M 656M 4.78M 5.53M 4.48M 4.09M 7.69M 528M 7.73M 53.18M 20.73M 267M 20.77M 20.31M 886M
Logo PREDILIFE
PREDILIFE specializes in the development of predictive tests, particularly in the field of oncology. The company has MammoRisk®, a breast cancer predictive test that uses a first mammogram and a few questions to obtain a first risk assessment. A genetic test then makes it possible to estimate the risk of breast cancer more accurately. The technology used by MammoRisk® makes it possible to evaluate, from a database of individuals monitored over time, the risks of an individual compared to the future of his « closest » neighbours thanks to a database of over 1,000,000 American women, and over 300,000 French women. PREDILIFE also develops multi-pathology tests to screen for colon, prostate and lung cancer, melanoma and cardiovascular risks.
Employees
21
Date Price Change Volume
26-08-28 €1.120 0.00% 0
26-08-27 €1.120 +0.90% 100
26-08-26 €1.110 0.00% 0
26-08-25 €1.110 0.00% 22
26-08-24 €1.110 0.00% 100

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALPRE Stock